ITOS — iTeos Therapeutics Share News
0.000.00%
Last trade - 00:00- $448.68m
- -$66.75m
- $35.00m
Brief: iteos Appoints Jill Desimone To Its Board Of Directors
Brief: Iteos Therapeutics Tigit Program Clinical Data Readouts Anticipated In 2024
Brief: Iteos Reports Third Quarter 2023 Financial Results And Provides Business Updates
Brief: Millennium Management LLC Reports 5.8% Passive Stake In Iteos Therapeutics As Of October 17 - SEC Filing
U.S. STOCKS ON THE MOVE-Netflix, AMC Entertainment, Nike
U.S. STOCKS ON THE MOVE-Toll Brothers, AMC Entertainment, Peloton Interactive
Cancer drugmakers gain after Roche discloses positive data from drug study
U.S. STOCKS ON THE MOVE-Thermo Fisher Scientific, Heliogen, Foot Locker
U.S. STOCKS ON THE MOVE-Manchester United, Apellis Pharma, cancer drugmakers
Cancer drugmakers gain after Roche discloses positive data from drug study
Iteos Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Iteos Therapeutics Inc expected to post a loss of $1.03 a share - Earnings Preview
Brief: Iteos Therapeutics Files For Mixed Shelf Of Up To $300 Mln
Brief: Iteos Reports Q1 2023 Financial Results And Provides Business Updates
Iteos Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Iteos Therapeutics Inc expected to post a loss of 99 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Adobe, Five Below, Lennar
Brief: iTeos Reports Fourth Quarter Results, Provides Business Updates
Brief: Iteos Therapeutics Inc - Cash And Investment Balance Of $731.4Mm As Of December 31, 2022, Expected To Provide Runway Into 2026